Share information
252.00 €
-0.75 %
19/03/2026 17:35
-0.75 %
Open
High
Low
Volume
251.60 €
253.80 €
247.40 €
287,577
Latest News
13-Mar-2026
Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees
11-Mar-2026
BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
03-Mar-2026
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
26-Feb-2026
Strong Execution Fueling Sustained Company Growth